MedPage Today3y
Approaches to Primary Hyperlipidemia/Mixed Dyslipidemia
Alarming trends in the rates of premature coronary heart disease among younger women in wealthy nations prompted a group of U.S. researchers to try to pinpoint their risk factors for CHD ...
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and SHASTA-2 studies of investigational ...
MedPage Today3y
Approaches to Primary Hyperlipidemia/Mixed Dyslipidemia
Alarming trends in the rates of premature coronary heart disease among younger women in wealthy nations prompted a group of U.S. researchers to try to pinpoint their risk factors for CHD ...